Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.86
NAS:OCUL's Cash-to-Debt is ranked lower than
64% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:OCUL: 2.86 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OCUL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.36  Med: 5.43 Max: 8.23
Current: 2.86
1.36
8.23
Equity-to-Asset 0.56
NAS:OCUL's Equity-to-Asset is ranked lower than
58% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:OCUL: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OCUL' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.9  Med: 0.75 Max: 0.84
Current: 0.56
-2.9
0.84
Debt-to-Equity 0.50
NAS:OCUL's Debt-to-Equity is ranked lower than
58% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:OCUL: 0.50 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:OCUL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.21  Med: 0.22 Max: 0.5
Current: 0.5
-0.21
0.5
Debt-to-EBITDA -0.30
NAS:OCUL's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:OCUL: -0.30 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:OCUL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.55  Med: -0.37 Max: -0.2
Current: -0.3
-0.55
-0.2
Piotroski F-Score: 2
Altman Z-Score: -4.13
Beneish M-Score: -3.64
WACC vs ROIC
9.53%
-5802.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3167.90
NAS:OCUL's Operating Margin % is ranked lower than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:OCUL: -3167.90 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OCUL' s Operating Margin % Range Over the Past 10 Years
Min: -136710  Med: -2902.81 Max: -2182.69
Current: -3167.9
-136710
-2182.69
Net Margin % -3241.19
NAS:OCUL's Net Margin % is ranked lower than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:OCUL: -3241.19 )
Ranked among companies with meaningful Net Margin % only.
NAS:OCUL' s Net Margin % Range Over the Past 10 Years
Min: -140930  Med: -3039.94 Max: -2271.31
Current: -3241.19
-140930
-2271.31
ROE % -120.36
NAS:OCUL's ROE % is ranked lower than
75% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:OCUL: -120.36 )
Ranked among companies with meaningful ROE % only.
NAS:OCUL' s ROE % Range Over the Past 10 Years
Min: -120.36  Med: -58.38 Max: -53.61
Current: -120.36
-120.36
-53.61
ROA % -80.48
NAS:OCUL's ROA % is ranked lower than
75% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:OCUL: -80.48 )
Ranked among companies with meaningful ROA % only.
NAS:OCUL' s ROA % Range Over the Past 10 Years
Min: -80.48  Med: -55.74 Max: -42.17
Current: -80.48
-80.48
-42.17
ROC (Joel Greenblatt) % -938.87
NAS:OCUL's ROC (Joel Greenblatt) % is ranked lower than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:OCUL: -938.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OCUL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2049.81  Med: -1559.32 Max: -938.87
Current: -938.87
-2049.81
-938.87
3-Year EBITDA Growth Rate 25.70
NAS:OCUL's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:OCUL: 25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:OCUL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.85 Max: 25.7
Current: 25.7
0
25.7
3-Year EPS without NRI Growth Rate 25.50
NAS:OCUL's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:OCUL: 25.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:OCUL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 25.5
Current: 25.5
0
25.5
GuruFocus has detected 3 Warning Signs with Ocular Therapeutix Inc NAS:OCUL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OCUL's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

OCUL Guru Trades in Q3 2016

Jim Simons Sold Out
» More
Q4 2016

OCUL Guru Trades in Q4 2016

Jim Simons 145,100 sh (New)
» More
Q1 2017

OCUL Guru Trades in Q1 2017

Jim Simons 88,900 sh (-38.73%)
» More
Q2 2017

OCUL Guru Trades in Q2 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OCUL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OSTO:MVIR B, NAS:CGEN, OTCPK:RASP, NAS:REPH, TPE:4142, ASX:BNO, LSE:BVXP, NAS:BDSI, ROCO:6497, NAS:GTXI, NAS:NBRV, NAS:VBLT, LSE:IMM, WAR:SLV, NAS:OVID, XKRX:002630, XTER:B8F, OTCPK:ARPO, NAS:XOMA, XKRX:196170 » details
Traded in other countries:0OT.Germany,
Headquarter Location:USA
Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

Ocular Therapeutix is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

Top Ranked Articles about Ocular Therapeutix Inc

5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ocular Therapeutix, Inc. (Nasdaq:OCUL) To Contact The Firm
EQUITY ALERT UPDATE: Rosen Law Firm Announces Filing of Securities Class Action Against Ocular Therapeutix, Inc. - OCUL
DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
Bernstein Liebhard LLP Announces That Only 10 Days Remain To File A Motion For Lead Plaintiff In A Class Action Filed Against Ocular Therapeutix, Inc.
OCUL ALERT: Rosen Law Firm Reminds Ocular Therapeutix, Inc. Investors of Important Deadline in First Filed Class Action - OCUL
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
OCUL INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline – OCUL

Ratios

vs
industry
vs
history
PB Ratio 4.07
OCUL's PB Ratio is ranked higher than
54% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OCUL: 4.07 )
Ranked among companies with meaningful PB Ratio only.
OCUL' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 4.14 Max: 17.67
Current: 4.07
1.54
17.67
PS Ratio 70.00
OCUL's PS Ratio is ranked lower than
82% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. OCUL: 70.00 )
Ranked among companies with meaningful PS Ratio only.
OCUL' s PS Ratio Range Over the Past 10 Years
Min: 60.69  Med: 127.6 Max: 1057.5
Current: 70
60.69
1057.5
EV-to-EBIT -1.84
OCUL's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. OCUL: -1.84 )
Ranked among companies with meaningful EV-to-EBIT only.
OCUL' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.3  Med: -4.1 Max: -0.9
Current: -1.84
-31.3
-0.9
EV-to-EBITDA -1.89
OCUL's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. OCUL: -1.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCUL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32  Med: -4.15 Max: -0.9
Current: -1.89
-32
-0.9
EV-to-Revenue 58.07
OCUL's EV-to-Revenue is ranked lower than
75% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. OCUL: 58.07 )
Ranked among companies with meaningful EV-to-Revenue only.
OCUL' s EV-to-Revenue Range Over the Past 10 Years
Min: 22.6  Med: 95.5 Max: 910.8
Current: 58.07
22.6
910.8
Current Ratio 4.79
OCUL's Current Ratio is ranked higher than
58% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OCUL: 4.79 )
Ranked among companies with meaningful Current Ratio only.
OCUL' s Current Ratio Range Over the Past 10 Years
Min: 4.79  Med: 9.61 Max: 24.35
Current: 4.79
4.79
24.35
Quick Ratio 4.78
OCUL's Quick Ratio is ranked higher than
60% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. OCUL: 4.78 )
Ranked among companies with meaningful Quick Ratio only.
OCUL' s Quick Ratio Range Over the Past 10 Years
Min: 4.78  Med: 9.59 Max: 24.31
Current: 4.78
4.78
24.31
Days Inventory 85.55
OCUL's Days Inventory is ranked higher than
66% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. OCUL: 85.55 )
Ranked among companies with meaningful Days Inventory only.
OCUL' s Days Inventory Range Over the Past 10 Years
Min: 85.55  Med: 152.75 Max: 266.73
Current: 85.55
85.55
266.73
Days Sales Outstanding 52.12
OCUL's Days Sales Outstanding is ranked higher than
72% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. OCUL: 52.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCUL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.25  Med: 101.96 Max: 1642.5
Current: 52.12
40.25
1642.5
Days Payable 2.00
OCUL's Days Payable is ranked lower than
88% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. OCUL: 2.00 )
Ranked among companies with meaningful Days Payable only.
OCUL' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 3758.83 Max: 30399.29
Current: 2
2
30399.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.70
OCUL's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. OCUL: -19.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCUL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.7  Med: -9.85 Max: 0
Current: -19.7
-19.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.45
OCUL's Price-to-Net-Cash is ranked higher than
64% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OCUL: 6.45 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OCUL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.9  Med: 4.99 Max: 18.75
Current: 6.45
1.9
18.75
Price-to-Net-Current-Asset-Value 6.06
OCUL's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. OCUL: 6.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OCUL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.88  Med: 4.73 Max: 17.94
Current: 6.06
1.88
17.94
Price-to-Tangible-Book 4.07
OCUL's Price-to-Tangible-Book is ranked higher than
63% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. OCUL: 4.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OCUL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.74  Med: 4.18 Max: 17.27
Current: 4.07
1.74
17.27
Price-to-Median-PS-Value 0.55
OCUL's Price-to-Median-PS-Value is ranked higher than
72% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OCUL: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OCUL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.01 Max: 7.34
Current: 0.55
0.54
7.34
Earnings Yield (Greenblatt) % -54.35
OCUL's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. OCUL: -54.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OCUL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -107.5  Med: -24.35 Max: -3.2
Current: -54.35
-107.5
-3.2

More Statistics

Revenue (TTM) (Mil) $1.95
EPS (TTM) $ -2.27
Beta1.17
Short Percentage of Float22.06%
52-Week Range $4.70 - 11.91
Shares Outstanding (Mil)29.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2 2 58
EPS ($) -2.23 -1.89 -1.33
EPS without NRI ($) -2.23 -1.89 -1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}